Health Care·Biotechnology·$7.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.23 | N/A | -91.67% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.23 | N/A | -91.67% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to advancing their pipeline despite the lack of revenue.
Management did not provide specific revenue figures for the quarter.
The company remains focused on its ongoing clinical trials and product development.
ImmunityBio's earnings report showed a significant miss on EPS, which may raise concerns among investors about the company's financial health. Despite this, the stock reacted positively, gaining 1.24%, possibly due to optimism surrounding ongoing clinical trials. The lack of revenue figures and guidance indicates uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BIONTECH SE ADR
Aug 9, 2021